Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00978055 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00978055 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT00978055, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's liothyronine sodium 50 mcg tablets to King's Cytomel® 50 mcg tablets following a single, oral 100 mcg (2 x 50 mcg) dose administration under fasting conditions.
Interventions
- DRUG 1: Liothyronine Sodium Tablets
- DRUG 2: Cytomel® Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00978055
The ClinicalTrials.gov registry entry for NCT00978055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 1: Liothyronine Sodium Tablets is the first listed.
NCT00978055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00978055 about?
NCT00978055 is a clinical study titled "Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)". The objective of this study was to investigate the bioequivalence of Mylan's liothyronine sodium 50 mcg tablets to King's Cytomel® 50 mcg tablets following a single, oral 100 mcg (2 x 50 mcg) dose administration under fasting conditions.
What is the current status of trial NCT00978055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00978055?
The interventions under investigation include: 1: Liothyronine Sodium Tablets (DRUG), 2: Cytomel® Tablets (DRUG).
Who is sponsoring clinical trial NCT00978055?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.